This study is investigating a potential new treatment for diseases related to the complement alternative pathway.
In healthy individuals, the complement alternative pathway is a normal part of the body’s immune system which is the infection fighting part of the human body. However, problems related to the regulation of the complement alternative pathway are linked with some serious diseases.
* Participants must have received the Meningococcal Vaccine (Bexsero or Trumenba plus Menveo/Menactra/MPSV4) within the past 2.5 years
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!